Bernhard Hampl, Ph.D. Elected to Serve as Executive Chairman of the Board of Directors of Fresenius Kabi Pharmaceuticals Holding, Inc.

SCHAUMBURG, Ill.--(Business Wire)--
Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ), which acquired
APP Pharmaceuticals, Inc., September 10, 2008, today announced the election of
Bernhard Hampl, Ph.D. to its Board of Directors effective November 1, 2009. Dr.
Hampl, also named as Executive Chairman of the Board, succeedscurrent Chairman
Dr. Ulf M. Schneider. Dr. Schneider will continue to serve on the Board of
Directors and as a member of the Audit Committee.

"Dr. Hampl is one of the most experienced and well-respected leaders in the
generic pharmaceutical industry. His addition to the Board both strengthens and
broadens the depth of our industry expertise," said Dr. Schneider. "I am
confident that Dr. Hampl is the right person to serve as Executive Chairman and
know that he has the strategic and operational leadership experience that will
allow us to capitalize on the opportunities before us."

"I have been fortunate to have worked extensively in the generic pharmaceutical
field and have witnessed many changes within our industry. I am pleased to be
joining the Board of Fresenius Kabi Pharmaceuticals Holding and look forward to
using my experience to expand APP`s pipeline, while exploring new opportunities
that will position it for future growth," said Dr. Hampl.

Dr. Hampl also serves as a member of the Board of Directors of ChemWerth, Inc.,
a private corporation, and as an advisor to Advent International Corporation,
Farmhispania and Guidepoint Global.

During his notable career, Dr. Hampl worked for 15 years for Cyanamid GmbH and
its business units, Lederle and Durachemie GmbH, where he held positions as
Director, Research and Development, Technical Director and Plant Director. In
1995, Dr. Hampl joined Hexal AG, a leading manufacturer and marketer of generic
pharmaceuticals in Germany, and led business development opportunities in the
U.S. generics market. In October 1995, Hexal acquired 50 percent of Eon Labs,
Inc., and 100 percent ownership in 2000. During this time, Dr. Hampl served as
President and CEO. In July 2005, Sandoz, Inc., a division of Novartis AG,
completed its merger with Eon Labs and Dr. Hampl became the President and Chief
Executive Officer of Sandoz, Inc., the U.S. operating unit of Sandoz. He
resigned from Sandoz effective September 30, 2008. While CEO of Sandoz, Dr.
Hampl also served as a member of the Executive Board of the Generic
Pharmaceutical Association. He received his Ph.D. in pharmaceutical chemistry
from Ludwig-Maximillians University in Munich, Germany.

About APP Pharmaceuticals, Inc.

APP Pharmaceuticals, Inc. is a fully-integrated pharmaceutical company that
develops, manufactures and markets injectable pharmaceutical products with a
primary focus on the oncology, anti-infective, anesthetic/analgesic and critical
care markets. The company offers one of the most comprehensive product
portfolios used in hospitals, long-term care facilities, alternate care sites
and clinics within North America and manufactures a comprehensive range of
dosage formulations. Fresenius Kabi Pharmaceuticals Holding, Inc., a wholly
owned subsidiary of Fresenius Kabi AG, acquired APP Pharmaceuticals, Inc. on
September 10, 2008. For more information about APP Pharmaceuticals, Inc., please
visit the company`s Web site at www.APPpharma.com.

About Fresenius Kabi AG

Fresenius Kabi AG is the leader in infusion therapy and clinical nutrition in
Europe and in its most important countries of Latin America and Asia Pacific.
Fresenius Kabi`s core product range includes infusion solutions for fluid
substitution, blood volume expansion, I.V. drugs and parenteral nutrition, as
well as products for enteral nutrition. Furthermore, the company provides
concepts for ambulatory health care and is focused on managing and providing
home therapies. With the philosophy "Caring for life" and a comprehensive
product portfolio, the company aims at improving the quality of life of patients
all over the world. In 2008, Fresenius Kabi achieved sales of EUR 2,495 million
and an operating profit of EUR 443 million. For more information visit the
company`s Web site at www.fresenius-kabi.com. Fresenius Kabi AG is a 100%
subsidiary of Fresenius SE.

About Fresenius SE

Fresenius SE is a health care group with international operations, providing
products and services for dialysis, hospital and outpatient medical care. In
2008, group sales were approximately EUR 12.3 billion. On June 30, 2009 the
Fresenius Group had 127,692 employees worldwide. For more information visit the
company`s Web site at www.fresenius.com.

Forward-Looking Statement

The statements contained in this news release that are not purely historical are
forward-looking statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended. Forward-looking statements in this news
release include statements regarding our expectations, beliefs, hopes, goals,
intentions, initiatives or strategies, including statements regarding the
demand, supply and distribution of our products. Because these forward-looking
statements involve risks and uncertainties, there are important factors that
could cause actual results to differ materially from those in the
forward-looking statements. These factors include, but are not limited to, the
availability and pricing of ingredients used in the manufacture of
pharmaceutical products and the ability to successfully manufacture products in
a time-sensitive and cost effective manner. Additional relevant information
concerning risks can be found in the Fresenius Kabi Pharmaceuticals Holding,
Inc. 10-K for the fiscal year ending December 31, 2008 and other documents the
company has filed with the Securities and Exchange Commission.

The information contained in this news release is as of the date of this
release. Fresenius Kabi Pharmaceuticals Holding, Inc. does not assume any
obligation to update or revise these forward-looking statements to conform the
statement to actual results, new information, developments or changes in the
Company`s expectations.

APP Contact
APP Pharmaceuticals, Inc.
Debra Lynn Ross
Director, Corporate Communications
847-969-8026
dross@apppharma.com
or
Investor Inquiries
Hill & Knowlton
Christine Cassiano
310-633-9495
christine.cassiano@hillandknowlton.com

Copyright Business Wire 2009